Annual Report 2024
A YEAR IN REVIEW
Featured
VHIRspective 2024
by the Director, Begoña Benito, MD PhD
Looking back, moving forward: a landmark year for VHIR
We have inaugurated the new research building!
This iconic building, which has its own identity and represents the values of innovation and excellence that underpin our daily work, is one of the first parts of the new Vall d’Hebron
30 years of research
It has been 30 years since a group of researchers in Vall d'Hebron laid the foundations of what is now a benchmark research centre in our country.
We have organized a series of events celebrating the 30th anniversary of the Vall d’Hebron Research Institute.
Our Key Figures
2609
TOTAL STAFF
1331
RESEARCH STAFF
63.66
WOMEN STAFF
1501
NUMBER OF
PUBLICATIONS
PUBLICATIONS
7.13
AVERAGE IMPACT FACTOR
43.6
PUBLICATIONS LEADERSHIP
208
NEW PROJECT
& HR GRANTS
& HR GRANTS
29.05
GRANTS FUNDING
515
ONGOING PROJECTS
25
NUMBER OF INTRAMURAL PROJECTS & HR GRANTS
1.85
INTRAMURAL INVESTMENT TO SUPPORT TO RESEARCH
1.14
INTRAMURAL INVESTMENT ON HR GRANTS
244
NEW CLINICAL STUDIES
1039
ACTIVE CLINICAL STUDIES
638
NEW PATIENT INCLUSION
2
LICENSED PATENTS
1
SPIN-OFFS/START-UPS APPROVED
1.37
REVENUE FROM INNOVATION
Top Stories
Highlights
eCORE
Global Health
The aim of this eCORE is the study of those diseases that have a global impact in society. The groups will promote research diseases that affect a large number of people in order to improve society’s well-being and public health.
RESEARCH GROUPS
486
Publications
8.58
Average Impact Factor
75.51
%Q1
Chronic, Prevalent Diseases & Aging
This eCORE focuses on the study of chronic and prevalent diseases along people’s life, and the effect of aging in society’s well-being.
RESEARCH GROUPS
869
Publications
7.78
Average Impact Factor
73.53
%Q1
Woman & Child Health & Rare Diseases
The main objectives of this eCORE are the study of diseases that affect women and children, including maternal diseases and paediatric and early ages health issues, as well as rare diseases affecting a small number of people.
RESEARCH GROUPS
628
Publications
6.32
Average Impact Factor
69.75
%Q1
Brain & Mind and Behaviour
Research groups affiliated to this eCORE are focused on the study of diseases affecting the brain, mind and/or behaviour. These clinical conditions have a high personal, social and economic burden, leading to disability and reducing quality and life.
RESEARCH GROUPS
326
Publications
7.76
Average Impact Factor
75.46
%Q1
Cancer
The aim of the Cancer eCORE is to improve the outcome and quality of life of cancer patients. Cancer eCORE directs its efforts to unveil and understand the mechanisms of the cancer origin and progression. The ultimate goal is to translate this knowledge into new diagnostic, prognostic and therapeutic solutions. Our bench to bed comprehensive research includes the generation of relevant disease models, biomarker studies, drug development and clinical trials.
RESEARCH GROUPS
286
Publications
5.87
Average Impact Factor
72.03
%Q1
Personalised Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
Being the largest, the objective of this eCORE is the development of new diagnostic tools and the promotion of personalized medicine based or not on digital health through the use of molecular imaging and other medical imaging technologies, biochemistry, pharmacy, pathology anatomy, omics data and related disciplines.
RESEARCH GROUPS
654
Publications
7.05
Average Impact Factor
73.24
%Q1
Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
This eCORE is focused on the development of novel cutting-edge treatment and interventions, based on advanced therapies, nanomedicine and innovative surgical and transplant/donation procedures, with the clear aim of making such progresses readily available to patients in need.
RESEARCH GROUPS
660
Publications
7.09
Average Impact Factor
71.82
%Q1
Best Scientific Images
Partners and Acknowledgements
In this section we want to thank the support of the board of trustees and other governing bodies, the entities that have placed their trust in us by financing research projects, as well as all the citizens and patient’s associations because through their private donations they contribute to providing research funds. And, finally, to the patients and their families for their generosity in helping us on a day-to-day basis, whether in defining our mission, placing themselves at the center of research since they are the first to benefit, either as volunteers in the clinical trials.
